
  
    
      
        Background_NNP
        Expression_NNP profiling_VBG is_VBZ an_DT emerging_VBG experimental_JJ method_NN
        whereby_WRB RNA_NNP accumulation_NN in_IN cells_NNS and_CC tissues_NNS can_MD be_VB
        assayed_JJ for_IN many_JJ thousands_NNS of_IN genes_NNS simultaneously_RB in_IN a_DT
        single_JJ experiment_NN ._. There_EX are_VBP two_CD common_JJ experimental_JJ
        platforms_NNS for_IN expression_NN profiling_VBG ;_: redundant_JJ
        oligonucleotide_NN arrays_NNS (_( Affymetrix_NNP GeneChips_NNP )_) [_NN 1_CD ]_NN ,_, and_CC
        spotted_VBD cDNA_NN microarrays_NNS [_NN 2_CD 3_CD 4_CD ]_NN ._. The_DT Affymetrix_NNP
        GeneChips_NNP have_VBP the_DT inherent_JJ advantages_NNS of_IN redundancy_NN ,_,
        specificity_NN ,_, and_CC transportability_NN ;_: there_EX are_VBP typically_RB
        30_CD -_: 40_CD oligonucleotide_NN probes_NNS (_( features_NNS )_) designed_VBN against_IN
        each_DT gene_NN tested_VBN by_IN the_DT array_NN ,_, with_IN paired_VBN perfect-match_JJ
        and_CC mismatch_NN probes_NNS ,_, with_IN standardized_JJ factory_NN synthesis_NN of_IN
        arrays_NNS [_NN 5_CD 6_CD ]_NN ._. The_DT uniform_NN nature_NN of_IN the_DT arrays_NNS permits_VBZ
        databasing_VBG of_IN individual_JJ profiles_NNS ,_, which_WDT facilitates_NNS
        comparison_NN of_IN data_NNS generated_VBN by_IN different_JJ laboratories_NNS ._.
        Expression_NNP profiling_VBG has_VBZ led_VBN to_TO dramatic_JJ advances_NNS in_IN
        understanding_NN of_IN yeast_NN biology_NN ,_, where_WRB homogeneous_JJ cultures_NNS
        can_MD be_VB grown_VBN and_CC exposed_VBN to_TO timed_VBN environmental_JJ variables_NNS [_NN
        7_CD 8_CD 9_CD 10_CD 11_CD 12_CD ]_NN ._. Such_JJ studies_NNS have_VBP led_VBN to_TO the_DT rapid_JJ
        assignment_NN of_IN function_NN to_TO a_DT large_JJ number_NN of_IN anonymous_JJ gene_NN
        sequences_NNS ._. Large-scale_NNP expression_NN profiling_VBG studies_NNS of_IN
        tissues_NNS from_IN higher_JJR vertebrates_NNS are_VBP more_JJR challenging_VBG ,_, due_JJ
        to_TO the_DT higher_JJR complexity_NN of_IN the_DT genome_NN ,_, larger_JJR related_JJ gene_NN
        families_NNS ,_, and_CC incomplete_JJ genomic_JJ resources_NNS ._. Nevertheless_RB ,_,
        DNA_NNP microarrays_NNS have_VBP been_VBN successfully_RB applied_VBN in_IN the_DT
        analysis_NN of_IN aging_VBG and_CC caloric_JJ restriction_NN [_NN 13_CD ]_NN and_CC
        pulmonary_JJ fibrosis_NNS [_NN 14_CD ]_NN ._. And_CC many_JJ publications_NNS ,_,
        particularly_RB on_IN cancer_NN ,_, have_VBP appeared_VBN [_NN 14_CD 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN
        ._. Affymetrix_NNP has_VBZ recently_RB announced_VBN the_DT availability_NN of_IN the_DT
        U_NNP 133_CD GeneChip_NNP series_NN with_IN 33_CD ,_, 000_CD well-characterized_JJ human_JJ
        genes_NNS mined_JJ from_IN genomic_JJ sequence_NN ._. The_DT nearly_RB complete_JJ
        ascertainment_NN of_IN genes_NNS in_IN the_DT human_JJ genome_NN should_MD make_VB
        expression-profiling_JJ studies_NNS of_IN human_JJ tissues_NNS particularly_RB
        powerful_JJ ._. However_RB ,_, identification_NN of_IN the_DT sources_NNS of_IN
        experimental_JJ variability_NN ,_, and_CC knowledge_NN of_IN the_DT relative_JJ
        contribution_NN of_IN variation_NN from_IN each_DT source_NN ,_, is_VBZ critical_JJ for_IN
        appropriate_JJ experimental_JJ design_NN in_IN expression_NN profiling_VBG
        experiments_NNS ._.
        Mills_NNP and_CC Gordon_NNP recently_RB studied_VBD the_DT relative_JJ
        contribution_NN of_IN experimental_JJ variability_NN of_IN probe_NN
        production_NN on_IN the_DT reproducibility_NN of_IN microarray_NN results_NNS
        using_VBG mixed_JJ murine_NN tissue_NN RNA_NNP on_IN Affymetrix_NNP Mu_NNP 11_CD K_NNP GeneChips_NNP
        [_NN 20_CD ]_NN ._. In_IN their_PRP$ study_NN ,_, the_DT same_JJ RNA_NNP preparation_NN was_VBD used_VBN
        as_IN a_DT template_NN for_IN distinct_JJ cDNA_NN /_NN cRNA_NN amplifications_NNS and_CC
        hybridizations_NNS ._. An_DT additional_JJ variable_JJ studied_VBN was_VBD the_DT
        effect_NN of_IN different_JJ laboratories_NNS processing_VBG the_DT same_JJ RNAs_NNP ._.
        The_DT authors_NNS found_VBD relatively_RB poor_JJ concordance_NN between_IN
        duplicate_VB arrays_NNS ,_, with_IN an_DT average_NN of_IN 12_CD %_NN increase_NN /_NN decrease_NN
        calls_VBZ between_IN the_DT same_JJ RNA_NNP processed_VBD in_IN parallel_JJ and_CC
        hybridized_JJ to_TO two_CD Mu_NNP 11_CD K-A_NNP microarrays_NNS ._. The_DT authors_NNS
        concluded_VBD that_IN there_EX was_VBD substantial_JJ experimental_JJ
        variability_NN in_IN the_DT experimental_JJ procedure_NN ,_, necessitating_VBG
        extensive_JJ filtering_VBG and_CC large_JJ numbers_NNS of_IN arrays_NNS to_TO detect_VB
        accurate_JJ gene_NN expression_NN changes_NNS (_( LUT_NNP :_: look-up_JJ tables_NNS )_) [_NN 20_CD
        ]_NN ._. In_IN our_PRP$ laboratory_NN ,_, we_PRP have_VBP processed_VBN over_IN 1_CD ,_, 200_CD
        Affymetrix_NNP arrays_NNS ,_, and_CC have_VBP found_VBN significantly_RB higher_JJR
        experimental_JJ reproducibility_NN (_( R_NN 2_CD =_SYM 0_CD ._. 979_CD for_IN new_JJ generation_NN
        U_NNP 74_CD A_DT version_NN 2_CD murine_NN arrays_NNS or_CC human_JJ U_NNP 95_CD series_NN ,_, see_VB
        Result_NN and_CC Discussion_NNP )_) ._. In_IN addition_NN ,_, a_DT recent_JJ publication_NN
        of_IN a_DT single_JJ human_JJ patient_NN ,_, where_WRB RNA_NNP was_VBD prepared_VBN from_IN two_CD
        distinct_JJ breast_NN tumors_NNS ,_, and_CC placed_VBD on_IN duplicate_VB U_NNP 95_CD A_DT
        GeneChips_NNP (_( four_CD chips_NNS total_JJ )_) found_VBD a_DT very_RB low_JJ degree_NN of_IN
        experimental_JJ variability_NN between_IN microarrays_NNS (_( R_NN 2_CD =_SYM 0_CD ._. 995_CD )_) ,_,
        and_CC between_IN the_DT two_CD tumors_NNS (_( R_NN 2_CD =_SYM 0_CD ._. 987_CD )_) [_NN 21_CD ]_NN ._. The_DT marked_VBD
        differences_NNS in_IN experimental_JJ variability_NN between_IN
        laboratories_NNS could_MD be_VB due_JJ to_TO different_JJ quality_NN control_NN
        protocols_NNS (_( see_VB http_NN :_: /_NN /_NN microarray_NN ._. cnmcresearch_NN ._. org_NN )_) ,_, newer_JJR
        more_RBR robust_JJ Affymetrix_NNP arrays_NNS now_RB available_JJ (_( murine_NN Mu_NNP 11_CD K_NNP
        versus_CC U_NNP 74_CD A_DT version_NN 2_CD and_CC new_JJ generation_NN human_JJ U_NNP 95_CD series_NN )_) ,_,
        use_NN of_IN more_JJR recent_JJ algorithms_NNS for_IN data_NNS interpretation_NN ,_, or_CC
        due_JJ to_TO more_RBR consistent_JJ processing_NN of_IN RNA_NNP ,_, cDNA_NN ,_, and_CC cRNA_NN in_IN
        the_DT same_JJ laboratory_NN ._.
        The_DT previous_JJ studies_NNS did_VBD not_RB systematically_RB address_VB the_DT
        reproducibility_NN of_IN GeneChip_NNP hybridization_NN (_( e_SYM ._. g_SYM ._. the_DT same_JJ
        biotinylated_JJ cRNA_NN on_IN two_CD different_JJ microarrays_NNS )_) ._. In_IN
        addition_NN to_TO lingering_VBG questions_NNS concerning_VBG variability_NN due_JJ
        to_TO specific_JJ experimental_JJ procedures_NNS ,_, there_EX are_VBP other_JJ
        possible_JJ sources_NNS of_IN variability_NN that_WDT have_VBP not_RB yet_RB been_VBN
        investigated_VBN ,_, specifically_RB tissue_NN heterogeneity_NN and_CC
        inter-individual_JJ variation_NN ._. The_DT latter_JJ two_CD sources_NNS of_IN
        variability_NN are_VBP particularly_RB important_JJ in_IN human_JJ expression_NN
        profiling_VBG studies_NNS ._. The_DT study_NN of_IN human_JJ tissues_NNS often_RB
        involves_VBZ the_DT use_NN of_IN tissue_NN biopsies_NNS ,_, where_WRB a_DT relatively_RB
        limited_JJ region_NN of_IN an_DT organ_NN is_VBZ sampled_VBN ._. Tissue_NNP heterogeneity_NN
        and_CC sampling_VBG error_NN might_MD be_VB expected_VBN to_TO introduce_VB
        significant_JJ variability_NN in_IN expression_NN profiles_NNS ._. Second_JJ ,_,
        tissues_NNS may_MD derive_VB from_IN individuals_NNS from_IN different_JJ ethnic_JJ
        backgrounds_NNS ;_: humans_NNS are_VBP highly_RB outbred_JJ ,_, leading_VBG to_TO the_DT
        potential_NN of_IN significant_JJ polymorphic_JJ noise_NN (_( herein_NN called_VBN
        "_'' SNP_NNP noise_NN "_'' )_) between_IN individuals_NNS unrelated_JJ to_TO the_DT disease_NN
        or_CC variable_JJ under_IN study_NN ._. SNP_NNP noise_NN also_RB exists_VBZ between_IN
        different_JJ inbred_JJ mouse_NN strains_NNS ,_, and_CC some_DT experiments_NNS have_VBP
        normalized_JJ this_DT effect_NN by_IN breeding_VBG the_DT same_JJ mutation_NN on_IN
        different_JJ strains_NNS ,_, and_CC profiling_VBG each_DT individually_RB [_NN 22_CD ]_NN ._.
        Knowledge_NNP of_IN the_DT relative_JJ effect_NN of_IN each_DT experimental_JJ ,_,
        tissue_NN ,_, and_CC patient_NN variable_JJ on_IN expression_NN profiling_VBG
        results_NNS in_IN humans_NNS is_VBZ important_JJ ,_, so_IN that_IN appropriate_JJ
        experimental_JJ designs_NNS can_MD be_VB employed_VBN ._.
        We_PRP recently_RB reported_VBD the_DT design_NN and_CC production_NN of_IN a_DT
        highly_RB redundant_JJ oligonucleotide_NN microarray_NN for_IN analysis_NN of_IN
        human_JJ muscle_NN biopsies_NNS (_( Borup_NNP et_CC al_NN ._. 
        submitted_VBN )_) ._. This_DT MuscleChip_NNP contains_VBZ
        4_CD ,_, 601_CD probe_NN sets_NNS corresponding_JJ to_TO 3_CD ,_, 369_CD distinct_JJ genes_NNS and_CC
        ESTs_NNP expressed_VBD in_IN human_JJ muscle_NN ._. Each_DT probe_NN set_VBN contains_VBZ
        between_IN 16_CD to_TO 40_CD oligonucleotides_NNS ,_, such_JJ that_IN the_DT number_NN of_IN
        specific_JJ oligonucleotide_NN probes_NNS on_IN the_DT array_NN was_VBD
        138_CD ,_, 000_CD ._.
        Here_RB ,_, we_PRP utilize_VB this_DT MuscleChip_NNP to_TO investigate_VB the_DT
        relative_JJ significance_NN of_IN variables_NNS affecting_VBG expression_NN
        profiling_VBG data_NNS and_CC interpretation_NN ._. Specifically_RB ,_, we_PRP studied_VBD
        the_DT correlation_NN coefficients_NNS of_IN profiles_NNS considering_VBG the_DT
        following_JJ variables_NNS :_: 1_CD ._. variation_NN due_JJ to_TO probe_VB production_NN
        (_( same_JJ RNA_NNP )_) ;_: 2_CD ._. variation_NN due_JJ to_TO the_DT microarray_NN itself_PRP (_( same_JJ
        cRNA_NN on_IN different_JJ GeneChips_NNP )_) ;_: 3_CD ._. tissue_NN heterogeneity_NN
        (_( different_JJ regions_NNS of_IN the_DT same_JJ muscle_NN biopsy_NN )_) ;_: 4_CD ._.
        inter-patient_JJ variability_NN (_( SNP_NNP noise_NN )_) ;_: 5_CD ._. diagnosis_NN
        (_( underlying_VBG pathological_JJ variable_JJ )_) ;_: and_CC 6_CD ._. patient_NN age_NN ._.
        We_PRP have_VBP recently_RB reported_VBN generation_NN of_IN expression_NN
        profiling_VBG results_NNS using_VBG mixed_JJ patient_NN samples_NNS [_NN 23_CD ]_NN ._. Our_PRP$
        hypothesis_NNS was_VBD that_IN mixing_VBG of_IN RNA_NNP samples_NNS from_IN multiple_JJ
        regions_NNS of_IN muscle_NN biopsies_NNS ,_, and_CC from_IN multiple_JJ patients_NNS
        matched_VBN for_IN most_JJS variables_NNS (_( disease_NN ,_, age_NN ,_, sex_NN )_) ,_, would_MD
        effectively_RB normalize_VB both_DT intra-patient_JJ variability_NN
        (_( tissue_NN heterogeneity_NN )_) ,_, and_CC inter-patient_JJ variability_NN (_( SNP_NNP
        noise_NN ;_: e_SYM ._. g_SYM ._. normal_JJ human_JJ polymorphic_JJ variation_NN unrelated_JJ to_TO
        the_DT primary_JJ defect_NN )_) ._. Here_RB ,_, we_PRP test_VBP this_DT hypothesis_NNS
        directly_RB ,_, and_CC show_NN that_DT sample_NN mixing_VBG does_VBZ indeed_RB result_NN in_IN
        relatively_RB high_JJ sensitivity_NN and_CC specificity_NN for_IN gene_NN
        expression_NN changes_NNS that_WDT would_MD be_VB detected_VBN by_IN many_JJ
        individual_JJ expression_NN profiles_NNS ._. Thus_RB ,_, sample_NN mixing_VBG appears_VBZ
        to_TO be_VB an_DT appropriate_JJ first-pass_JJ method_NN to_TO obtain_VB the_DT most_RBS
        significant_JJ expression_NN changes_NNS ,_, while_IN using_VBG small_JJ numbers_NNS
        of_IN arrays_NNS ._.
      
      
        Results_NNS and_CC discussion_NN
        Fifty_NNP six_CD (_( 56_CD )_) different_JJ RNA_NNP samples_NNS were_VBD prepared_VBN from_IN
        different_JJ regions_NNS of_IN muscle_NN biopsies_NNS from_IN 28_CD individuals_NNS
        (_( 15_CD Duchenne_NNP muscular_JJ dystrophy_NN (_( DMD_NNP )_) patients_NNS ,_, 13_CD normal_JJ
        controls_NNS )_) ._. The_DT profiles_NNS of_IN five_CD of_IN the_DT DMD_NNP patients_NNS and_CC the_DT
        five_CD controls_NNS have_VBP been_VBN previously_RB reported_VBN using_VBG the_DT
        Affymetrix_NNP HuFL_NNP microarray_NN [_NN 23_CD ]_NN ;_: however_RB ,_, we_PRP re-tested_JJ
        these_DT same_JJ samples_NNS on_IN the_DT custom_NN MuscleChip_NNP (_( Borup_NNP et_CC al_NN ._. 
        submitted_VBN )_) for_IN comparison_NN to_TO the_DT
        other_JJ patients_NNS here_RB ._. All_DT RNAs_NNP were_VBD converted_VBN to_TO
        double-stranded_JJ cDNA_NN ,_, and_CC then_RB to_TO biotinylated_JJ cRNA_NN ._. The_DT
        cRNAs_NNS were_VBD then_RB hybridized_JJ to_TO the_DT MuscleChip_NNP either_CC singly_RB ,_,
        in_IN mixed_JJ groups_NNS ,_, or_CC both_DT ,_, as_IN described_VBN below_IN ._. In_IN total_JJ ,_, 34_CD
        hybridizations_NNS were_VBD performed_VBN ,_, scanned_JJ ,_, and_CC the_DT data_NNS
        statistically_RB analyzed_VBD using_VBG Affymetrix_NNP Microarray_NNP Suite_NNP
        and_CC Excel_NNP ._. Quality_JJ control_NN criteria_NNS were_VBD as_IN described_VBN on_IN
        our_PRP$ web_NN site_NN (_( http_NN :_: /_NN /_NN microarray_NN ._. cnmcresearch_NN ._. org_NN ,_, link_NN to_TO
        "_'' programs_NNS in_IN genomic_JJ applications_NNS "_'' )_) ,_, and_CC included_VBD
        sufficient_JJ cRNA_NN amplification_NN ,_, and_CC adequate_JJ
        post-hybridization_JJ scaling_NN factors_NNS ._. Scaling_NNP factors_NNS
        (_( normalization_NN needed_VBN to_TO reach_VB a_DT common_JJ target_NN intensity_NN )_)
        ranged_VBD from_IN 0_CD ._. 46_CD to_TO 3_CD ._. 28_CD (_( Table_NNP 1_LS )_) ._. All_DT raw_JJ image_NN files_NNS ,_,
        processed_VBN image_NN files_NNS ,_, and_CC difference_NN analyses_NNS are_VBP posted_VBN
        on_IN a_DT web-queried_JJ SQL_NNP database_NN interface_NN to_TO our_PRP$ Affymetrix_NNP
        LIMS_NNP Oracle_NNP warehouse_NN (_( see_VB
        http_NN :_: /_NN /_NN microarray_NN ._. cnmcresearch_NN ._. org_NN :_: link_NN to_TO "_'' programs_NNS in_IN
        genomic_JJ applications_NNS "_'' ,_, "_'' data_NNS "_'' ,_, "_'' human_JJ "_'' )_) ._.
        Among_IN the_DT 4_CD ,_, 601_CD probe_NN sets_NNS on_IN the_DT Affymetrix_NNP custom_NN
        muscle_NN microarray_NN ,_, we_PRP found_VBD a_DT consistent_JJ percentage_NN of_IN
        "_'' present_JJ "_'' calls_VBZ for_IN each_DT of_IN the_DT 34_CD cRNA_NN samples_NNS tested_VBN
        (_( Duchenne_NNP dystrophy_NN ,_, 28_CD arrays_NNS ,_, 48_CD ._. 2_LS %_NN ±_NN 6_CD ._. 1_CD %_NN ;_: controls_VBZ 6_CD
        arrays_NNS ,_, 53_CD ._. 3_LS %_NN ±_NN 1_CD ._. 4_CD %_NN )_) ._. To_TO test_VB for_IN inter-array_JJ variability_NN ,_,
        two_CD different_JJ hybridization_NN solutions_NNS were_VBD applied_VBN to_TO
        duplicate_VB arrays_NNS ,_, and_CC correlation_NN coefficients_NNS determined_VBN ._.
        A_DT high_JJ correlation_NN coefficient_NN was_VBD found_VBN in_IN this_DT analysis_NN ,_,
        suggesting_VBG that_IN inter-array_JJ variability_NN of_IN the_DT MuscleChip_NNP
        used_VBD was_VBD a_DT relatively_RB minor_JJ variable_JJ (_( Patient_NNP 3_CD a_DT and_NN
        3_CD a-duplicate_JJ R_NN 2_CD =_SYM 0_CD ._. 96_CD and_CC percent_NN shared_VBD [_NN No_DT Change_NNP (_( NC_NNP )_) ]_NN
        calls_VBZ by_IN Microarray_NNP Suite_NNP software_NN was_VBD 99_CD %_NN ;_: Patient_NNP 3_CD b_SYM and_CC
        3_CD b-duplicate_JJ R_NN 2_CD =_SYM 0_CD ._. 98_CD and_CC percent_NN NC_NNP was_VBD 98_CD %_NN ;_: Table_NNP 1_LS )_) ._.
        The_DT high_JJ reproducibility_NN of_IN Affymetrix_NNP array_NN results_NNS is_VBZ
        consistent_JJ with_IN other_JJ data_NNS in_IN our_PRP$ laboratory_NN ,_, and_CC from_IN
        previously_RB published_VBN data_NNS [_NN 6_CD 21_CD 23_CD 24_CD ]_NN ,_, and_CC shows_VBZ that_IN
        experimental_JJ variability_NN associated_VBN with_IN hybridization_NN and_CC
        scanning_VBG of_IN highly_RB redundant_JJ oligonucleotide_NN GeneChips_NNP is_VBZ
        not_RB a_DT major_JJ source_NN of_IN experimental_JJ variability_NN ._.
        Given_VBN the_DT previous_JJ report_NN suggesting_VBG that_IN the_DT conversion_NN
        of_IN RNA_NNP to_TO biotinylated_JJ cRNA_NN probe_NN was_VBD a_DT major_JJ source_NN of_IN
        variability_NN in_IN murine_NN array_NN experiments_NNS [_NN 20_CD ]_NN ,_, we_PRP tested_VBD
        a_DT series_NN of_IN murine_NN RNA_NNP from_IN different_JJ sources_NNS ,_, using_VBG the_DT
        newer_JJR generation_NN U_NNP 74_CD Av_NNP 2_CD GeneChips_NNP ._. One_CD series_NN of_IN samples_NNS
        was_VBD from_IN murine_NN spleens_NNS ,_, where_WRB spleens_NNS from_IN multiple_JJ
        animals_NNS for_IN each_DT variable_NN under_IN study_NN were_VBD mixed_JJ ,_, RNA_NNP
        isolated_VBD ,_, RNA_NNP samples_NNS split_NN ,_, and_CC duplicate_VB cDNA_NN ,_, cRNA_NN ,_, and_CC
        hybridizations_NNS processed_VBN in_IN parallel_JJ for_IN each_DT RNA_NNP (_( Fig_NNP ._. 1_LS ,_,
        "_'' KNagaraju_NNP "_'' samples_NNS )_) ._. We_PRP also_RB compared_VBD RNAs_NNP processed_VBD from_IN
        parallel_JJ murine_NN myogenic_JJ cell_NN cultures_NNS (_( Fig_NNP ._. 1_LS ,_, "_'' VSM_NNP "_''
        samples_NNS )_) ,_, where_WRB each_DT profile_NN was_VBD from_IN a_DT different_JJ cell_NN
        culture_NN ._. Finally_RB ,_, we_PRP used_VBD a_DT series_NN of_IN murine_NN muscle_NN tissues_NNS
        from_IN normal_JJ and_CC dystrophin-deficient_JJ mice_NNS ,_, where_WRB each_DT
        profile_NN was_VBD from_IN a_DT different_JJ series_NN of_IN complete_JJ
        gastrocnemius_JJ muscles_NNS (_( Fig_NNP ._. 1_LS ,_, "_'' FBooth_NNP "_'' samples_NNS )_) ._. The_DT data_NNS
        from_IN these_DT 42_CD murine_NN U_NNP 74_CD Av_NNP 2_CD profiles_NNS were_VBD then_RB analyzed_VBN by_IN
        unsupervised_JJ clustering_VBG [_NN 25_CD ]_NN to_TO determine_VB which_WDT profiles_NNS
        were_VBD most_RBS closely_RB related_VBN to_TO each_DT other_JJ (_( Fig_NNP ._. 1_LS )_) ._. This_DT
        analysis_NN shows_VBZ that_IN the_DT different_JJ sources_NNS of_IN RNA_NNP cluster_NN
        together_RB ,_, as_IN expected_VBN ._. Importantly_NNP ,_, the_DT same_JJ RNA_NNP used_VBD as_IN a_DT
        template_NN for_IN two_CD distinct_JJ cDNA_NN /_NN cRNA_NN preparations_NNS and_CC
        hybridizations_NNS showed_VBD a_DT high_JJ correlation_NN coefficient_NN (_( R_NN 2_CD =_SYM
        0_CD ._. 99_CD for_IN five_CD of_IN the_DT six_CD samples_NNS ,_, with_IN average_JJ R_NN 2_CD =_SYM 0_CD ._. 978_CD )_)
        (_( Fig_NNP ._. 1_LS )_) ._. The_DT large_JJ muscle_NN group_NN profiles_NNS (_( FBooth_NNP samples_NNS )_)
        showed_VBD excellent_JJ correlation_NN ,_, both_DT with_IN respect_NN to_TO
        diagnosis_NN ;_: however_RB here_RB there_EX was_VBD no_DT sampling_VBG error_NN as_IN the_DT
        entire_JJ muscle_NN group_NN was_VBD used_VBN rather_RB than_IN isolated_VBN biopsies_NNS ._.
        Finally_RB ,_, the_DT parallel_JJ tissue_NN culture_NN experiments_NNS (_( VSM_NNP
        samples_NNS )_) showed_VBD greater_JJR variability_NN between_IN duplicates_NNS ,_,
        suggesting_VBG that_DT tissue_NN culture_NN conditions_NNS may_MD be_VB more_RBR
        subject_JJ to_TO variability_NN than_IN 
        in_IN vivo_NN tissues_NNS (_( Fig_NNP ._. 1_LS )_) ._. This_DT murine_NN
        data_NN shows_VBZ that_DT variability_NN from_IN different_JJ cDNA-cRNA_JJ
        reactions_NNS is_VBZ very_RB low_JJ (_( R_NN 2_CD =_SYM 0_CD ._. 978_CD )_) ._.
        To_TO analyze_VB the_DT impact_NN of_IN intra-patient_JJ variability_NN
        (_( tissue_NN heterogeneity_NN )_) ,_, inter-patient_JJ variability_NN
        (_( polymorphic_JJ noise_NN in_IN outbred_JJ populations_NNS )_) ,_, and_CC the_DT effect_NN
        of_IN sample_NN mixing_VBG on_IN the_DT sensitivity_NN of_IN detection_NN of_IN gene_NN
        expression_NN differences_NNS between_IN patient_NN groups_NNS ,_, we_PRP conducted_VBD
        a_DT series_NN of_IN individual_JJ and_CC mixed_JJ profiling_VBG (_( Table_NNP 1_LS )_) ._.
        Muscle_NNP biopsies_NNS from_IN five_CD 4_CD -_: 6_CD yr_NN old_JJ DMD_NNP patients_NNS ,_, and_CC five_CD
        10_CD -_: 12_CD yr_NN old_JJ patients_NNS were_VBD selected_VBN ,_, each_DT biopsy_NN split_NN into_IN
        two_CD parts_NNS ,_, and_CC RNA_NNP isolated_VBD independently_RB from_IN each_DT of_IN the_DT
        20_CD biopsy_NN fragments_NNS ._. For_IN these_DT ten_CD DMD_NNP patients_NNS ,_, the_DT two_CD
        different_JJ regions_NNS of_IN the_DT same_JJ biopsy_NN were_VBD expression_NN
        profiled_VBN both_DT individually_RB (_( 20_CD profiles_NNS )_) ,_, and_CC also_RB mixed_JJ
        into_IN four_CD pools_NNS where_WRB each_DT pool_NN originated_VBN from_IN distinct_JJ
        RNA_NNP samples_NNS (_( Table_NNP 1_LS )_) ._. The_DT resulting_VBG profiles_NNS were_VBD also_RB
        compared_VBN to_TO previously_RB reported_VBD mixed_JJ 6_CD -_: 9_CD yr_NN old_JJ DMD_NNP
        patient_NN cRNAs_NNS ,_, and_CC mixed_JJ 6_CD -_: 9_CD yr_NN old_JJ control_NN cRNAs_NNS [_NN 23_CD ]_NN ,_,
        as_IN mentioned_VBN above_IN ._.
        As_IN an_DT initial_JJ statistical_JJ analysis_NN ,_, we_PRP used_VBD Affymetrix_NNP
        software_NN to_TO define_VB genes_NNS that_WDT showed_VBD expression_NN changes_NNS
        (_( Increased_VBN ,_, Decreased_NNP or_CC Marginal_JJ )_) in_IN expression_NN levels_NNS
        between_IN pairs_NNS of_IN profiles_NNS (_( difference_NN analyses_NNS )_) ._. This_DT
        method_NN of_IN data_NNS interpretation_NN showed_VBD that_IN some_DT muscle_NN
        biopsies_NNS showed_VBD very_RB little_JJ variance_NN between_IN different_JJ
        regions_NNS of_IN the_DT same_JJ biopsy_NN ,_, while_IN other_JJ patient_NN biopsies_NNS
        showed_VBD considerable_JJ variability_NN (_( see_VB Fig_NNP ._. 2_LS for_IN
        representative_NN scatter_NN graphs_NNS )_) ._. Expressing_NNP this_DT variance_NN as_IN
        a_DT percentage_NN of_IN "_'' Diff_NNP Calls_NNS "_'' between_IN the_DT two_CD regions_NNS of_IN the_DT
        same_JJ biopsy_NN ,_, as_IN determined_VBN by_IN Affymetrix_NNP default_NN
        algorithms_NNS ,_, we_PRP found_VBD considerable_JJ variability_NN in_IN the_DT
        similarity_NN of_IN profiles_NNS ,_, with_IN values_NNS ranging_VBG from_IN 1_CD ._. 5_CD %_NN to_TO
        18_CD %_NN of_IN the_DT 4_CD ,_, 601_CD probe_NN sets_NNS studied_VBN (_( 4_CD ._. 99_CD %_NN ±_NN 4_CD ._. 94_CD %_NN )_) ._. This_DT
        data_NNS suggests_VBZ that_DT tissue_NN heterogeneity_NN (_( intra-patient_JJ
        variability_NN )_) can_MD be_VB a_DT major_JJ source_NN of_IN variation_NN in_IN
        expression_NN profiling_VBG experiments_NNS ,_, even_RB when_WRB using_VBG
        relatively_RB large_JJ pieces_NNS (_( 50_CD mg_NN )_) of_IN relatively_RB homogeneous_JJ
        tissues_NNS (_( such_JJ as_IN muscle_NN )_) ._.
        The_DT most_RBS common_JJ strategy_NN for_IN interpreting_VBG Affymetrix_NNP
        microarray_NN data_NNS is_VBZ to_TO use_VB two_CD profile_NN comparisons_NNS ,_, with_IN an_DT
        arbitrary_JJ threshold_NN for_IN "_'' significant_JJ fold-change_JJ "_'' in_IN
        expression_NN levels_NNS ._. Typically_RB ,_, multiple_JJ arrays_NNS are_VBP compared_VBN ,_,
        with_IN those_DT gene_NN expression_NN changes_NNS showing_VBG the_DT most_RBS
        consistent_JJ fold_VB changes_NNS prioritized_JJ ,_, although_IN other_JJ methods_NNS
        have_VBP been_VBN reported_VBN [_NN 13_CD 22_CD 26_CD 27_CD ]_NN ._. To_TO study_VB inter-patient_JJ
        variability_NN ,_, we_PRP defined_VBD the_DT gene_NN expression_NN changes_NNS
        surviving_VBG four_CD pairwise_NN comparisons_NNS with_IN mixed_JJ control_NN
        samples_NNS ,_, as_IN we_PRP have_VBP previously_RB described_VBN [_NN 23_CD ]_NN ._. Briefly_NNP ,_,
        four_CD comparisons_NNS were_VBD done_VBN by_IN Affymetrix_NNP software_NN (_( eg_NN ._. DMD_NNP
        1_CD a_DT versus_CC control_NN 1_CD a_SYM ;_: DMD_NNP 1_CD a_DT versus_CC control_NN 1_CD b_SYM ;_: DMD_NNP 1_CD b_SYM
        versus_CC control_NN 1_CD a_SYM ;_: DMD_NNP 1_CD b_SYM versus_CC control_NN 1_CD b_SYM )_) ._. The_DT four_CD data_NN
        sets_NNS were_VBD then_RB compared_VBN ,_, with_IN only_RB those_DT gene_NN expression_NN
        changes_NNS that_WDT showed_VBD >_NN 2_CD -_: fold_VB change_NN in_IN all_DT four_CD
        comparisons_NNS (_( four_CD comparison_NN survival_NN method_NN )_) ._. The_DT number_NN
        of_IN surviving_VBG diff_NN calls_VBZ by_IN this_DT method_NN ranged_VBD from_IN 250_CD to_TO
        463_CD (_( 355_CD ±_NN 80_CD )_) (_( Table_NNP 1_LS )_) ._. Interestingly_RB ,_, those_DT patients_NNS
        showing_VBG considerable_JJ variation_NN between_IN different_JJ regions_NNS of_IN
        the_DT same_JJ biopsy_NN did_VBD not_RB show_VB a_DT corresponding_JJ decrease_NN in_IN
        the_DT number_NN of_IN gene_NN expression_NN changes_NNS surviving_VBG the_DT
        iterative_JJ comparisons_NNS to_TO controls_NNS (_( Table_NNP 1_LS )_) ._. This_DT suggests_VBZ
        (_( but_CC does_VBZ not_RB prove_VB )_) the_DT most_RBS significant_JJ changes_NNS might_MD be_VB
        shared_VBN ,_, independent_JJ of_IN tissue_NN variability_NN (_( see_VB below_IN )_) ._.
        A_DT different_JJ statistical_JJ method_NN to_TO determine_VB the_DT effect_NN
        of_IN the_DT different_JJ variables_NNS under_IN study_NN is_VBZ to_TO perform_VB
        hierarchical_JJ cluster_NN analysis_NN using_VBG nearest_JJS neighbor_NN
        statistical_JJ methods_NNS [_NN 25_CD ]_NN ._. Here_RB ,_, we_PRP subjected_VBN all_DT
        profiles_NNS to_TO unsupervised_JJ cluster_NN analysis_NN ,_, as_IN a_DT means_NN of_IN
        determining_VBG which_WDT variables_NNS had_VBD the_DT greatest_JJS effect_NN (_( e_SYM ._. g_SYM ._.
        intra-patient_JJ variability_NN [_NN different_JJ regions_NNS of_IN biopsy_NN ]_NN ,_,
        versus_CC diagnosis_NN [_NN DMD_NNP vs_NNS control_VBP ]_NN ,_, versus_CC inter-patient_JJ
        variability_NN [_NN DMD_NNP patients_NNS in_IN same_JJ age_NN group_NN ]_NN ,_, versus_CC age_NN of_IN
        patient_NN )_) ._. For_IN this_DT analysis_NN ,_, we_PRP used_VBD the_DT fluorescence_NN
        intensity_NN of_IN each_DT probe_NN set_VBN (_( Average_NNP difference_NN )_) ,_, after_IN
        data_NNS scrubbing_VBG to_TO remove_VB genes_NNS that_WDT showed_VBD expression_NN
        levels_NNS near_IN background_NN (_( "_'' Absent_VB "_'' Calls_NNS )_) for_IN all_DT profiles_NNS
        (_( Fig_NNP ._. 3_LS )_) ._. This_DT analysis_NN shows_VBZ that_WDT duplicate_VB profiles_NNS of_IN
        the_DT same_JJ cRNA_NN hybridization_NN solution_NN are_VBP the_DT most_RBS highly_RB
        related_VBN (_( Patient_NNP 3_CD a_DT and_NN duplicate_VB (_( 3_CD a-d_JJ )_) ;_: 3_CD b_SYM and_CC duplicate_VB
        (_( 3_CD b-d_JJ )_) )_) ,_, consistent_JJ with_IN the_DT high_JJ correlation_NN found_VBN by_IN the_DT
        comparisons_NNS using_VBG Affymetrix_NNP Microarray_NNP Suite_NNP software_NN
        described_VBD above_IN ._. Again_RB ,_, this_DT reflects_VBZ the_DT low_JJ amount_NN of_IN
        combined_VBN experimental_JJ variability_NN intrinsic_JJ to_TO the_DT
        laboratory_NN processing_NN of_IN RNA_NNP ,_, cDNA_NN ,_, cRNA_NN and_CC
        hybridization_NN ._.
        When_WRB comparing_VBG two_CD different_JJ regions_NNS of_IN the_DT same_JJ biopsy_NN
        [_NN intra-patient_JJ variability_NN ]_NN ,_, we_PRP found_VBD widely_RB varying_VBG
        results_NNS ,_, depending_VBG on_IN the_DT patient_NN studied_VBN (_( Fig_NNP ._. 3_LS )_) ._. For_IN
        example_NN ,_, some_DT individual_JJ patients_NNS showed_VBD very_RB closely_RB
        related_VBN profiles_NNS that_WDT approached_VBD the_DT similarity_NN of_IN
        duplicate_VB arrays_NNS on_IN the_DT same_JJ cRNA_NN (_( Fig_NNP ._. 2_LS ;_: profiles_NNS 6_CD a_DT ,_, 6_CD b_SYM ;_:
        10_CD a_DT ,_, 10_CD b_SYM )_) ._. On_IN the_DT other_JJ hand_NN ,_, some_DT patients_NNS showed_VBD very_RB
        distantly_RB related_VBN profiles_NNS for_IN two_CD regions_NNS of_IN the_DT same_JJ
        biopsy_NN (_( Fig_NNP ._. 3_LS ;_: profiles_NNS 1_CD a_DT ,_, 1_CD b_SYM ;_: 4_CD a_DT ,_, 4_CD b_SYM ;_: 9_CD a_DT ,_, 9_CD b_SYM )_) ._.
        Importantly_NNP ,_, the_DT variation_NN caused_VBN by_IN intra-patient_JJ tissue_NN
        variation_NN often_RB overshadowed_VBD all_DT other_JJ variables_NNS ._. For_IN
        example_NN ,_, a_DT profile_NN from_IN DMD_NNP patient_NN 9_CD (_( 9_CD a_DT )_) clustered_VBN with_IN
        the_DT normal_JJ controls_NNS ,_, rather_RB than_IN with_IN the_DT other_JJ DMD_NNP
        patients_NNS (_( Fig_NNP ._. 3_LS )_) ._. The_DT histopathology_NN of_IN this_DT patient_NN was_VBD
        noted_VBN as_IN being_VBG unusually_RB variable_JJ in_IN severity_NN prior_RB to_TO
        expression_NN profiling_VBG ._. Also_RB ,_, unsupervised_JJ clustering_VBG was_VBD
        unable_JJ to_TO group_VB patients_NNS of_IN similar_JJ ages_NNS ,_, despite_IN DMD_NNP
        showing_VBG a_DT progressive_JJ clinical_JJ course_NN ._. We_PRP conclude_VBP that_IN
        intra-patient_JJ tissue_NN heterogeneity_NN is_VBZ a_DT major_JJ source_NN of_IN
        experimental_JJ variability_NN in_IN expression_NN profiling_VBG ,_, and_CC must_MD
        be_VB considered_VBN in_IN experimental_JJ design_NN ._.
        The_DT above_IN findings_NNS suggested_VBD that_IN both_DT intra-patient_JJ
        variability_NN (_( tissue_NN heterogeneity_NN )_) and_CC inter-patient_JJ
        variability_NN (_( polymorphic_JJ noise_NN )_) had_VBD major_JJ effects_NNS on_IN the_DT
        expression_NN profiles_NNS ._. One_CD method_NN to_TO control_VB for_IN these_DT
        sources_NNS of_IN noise_NN is_VBZ to_TO analyze_VB large_JJ numbers_NNS of_IN profiles_NNS ,_,
        both_DT on_IN multiple_JJ patients_NNS ,_, and_CC on_IN multiple_JJ regions_NNS of_IN
        tissue_NN from_IN each_DT patient_NN ._. This_DT would_MD allow_VB determinations_NNS
        of_IN p_NN values_NNS and_CC statistical_JJ significance_NN for_IN a_DT single_JJ
        controlled_VBN variable_JJ under_IN study_NN (_( e_SYM ._. g_SYM ._. DMD_NNP vs_NNS controls_NNS )_) ._. An_DT
        alternative_JJ method_NN is_VBZ to_TO experimentally_RB normalize_VB these_DT
        variables_NNS through_IN mixing_VBG of_IN samples_NNS from_IN patient_NN groups_NNS ;_:
        such_JJ mixing_VBG would_MD be_VB expected_VBN to_TO average_VB out_RP both_DT intra-_NN
        and_CC inter-patient_JJ variation_NN ._. The_DT expectation_NN is_VBZ that_IN the_DT
        most_RBS significant_JJ and_CC dramatic_JJ gene_NN expression_NN changes_NNS would_MD
        still_RB be_VB identified_VBN ,_, while_IN using_VBG many_JJ less_JJR profiles_NNS (_( and_CC
        thus_RB a_DT substantial_JJ reduction_NN in_IN cost_NN of_IN the_DT analyses_NNS )_) ._.
        To_TO test_VB for_IN the_DT relative_JJ sensitivity_NN of_IN interpretation_NN
        of_IN sample_NN mixing_VBG versus_CC individual_JJ profiles_NNS ,_, we_PRP mixed_JJ
        together_RB the_DT 10_CD cRNAs_NNS for_IN the_DT two_CD different_JJ age_NN groups_NNS of_IN
        DMD_NNP patients_NNS (_( samples_NNS 1_CD a_SYM -_: 5_CD b_SYM ;_: samples_NNS 6_CD a_SYM -_: 10_CD b_SYM )_) ._. For_IN this_DT
        analysis_NN ,_, we_PRP also_RB generated_VBD expression_NN profiles_NNS for_IN two_CD
        additional_JJ groups_NNS of_IN control_NN individuals_NNS ._. One_CD was_VBD a_DT second_RB
        set_NN of_IN five_CD normal_JJ male_JJ biopsies_NNS ages_NNS 5_CD -_: 12_CD yrs_NNS (_( controls_NNS
        2_CD a_DT ,_, 2_CD b_SYM )_) ,_, and_CC the_DT third_JJ control_NN set_VBN was_VBD three_CD normal_JJ
        age-matched_JJ female_JJ biopsies_NNS ages_NNS 4_CD -_: 13_CD yrs_NNS (_( controls_NNS 3_CD a_DT ,_, 3_CD b_SYM )_)
        (_( Fig_NNP ._. 4_LS )_) ._. As_IN with_IN the_DT original_JJ male_JJ control_NN group_NN (_( control_NN
        1_CD a_DT ,_, 1_CD b_SYM )_) ,_, two_CD different_JJ regions_NNS of_IN each_DT biopsy_NN were_VBD
        processed_VBN independently_RB through_IN the_DT biotinylated_JJ cRNA_NN step_NN ,_,
        and_CC then_RB equimolar_NN amounts_NNS of_IN cRNA_NN mixed_JJ for_IN hybridization_NN
        to_TO the_DT MuscleChip_NNP ._.
        All_DT 34_CD profiles_NNS (_( both_DT individual_NN and_CC mixed_JJ samples_NNS )_) were_VBD
        again_RB analyzed_VBN by_IN unsupervised_JJ hierarchical_JJ clustering_VBG
        (_( Fig_NNP ._. 4_LS )_) [_NN 25_CD ]_NN ._. As_IN described_VBD above_IN ,_, we_PRP scrubbed_JJ the_DT
        profiles_NNS to_TO eliminate_VB all_DT genes_NNS showing_VBG expression_NN levels_NNS
        consistently_RB at_IN or_CC below_IN background_NN hybridization_NN
        intensities_NNS by_IN requiring_VBG each_DT gene_NN to_TO show_VB a_DT "_'' Present_NN Call_VB "_''
        in_IN one_CD or_CC more_JJR of_IN the_DT 34_CD profiles_NNS ._.
        As_IN above_IN ,_, duplicate_VB profiles_NNS using_VBG the_DT same_JJ cRNA_NN
        hybridization_NN solution_NN on_IN different_JJ arrays_NNS ,_, whether_IN mixed_JJ
        or_CC individual_JJ samples_NNS ,_, showed_VBD very_RB highly_RB correlated_JJ
        results_NNS (_( very_RB low_JJ branch_NN on_IN dendrogram_NN )_) (_( Fig_NNP ._. 4_LS ;_: mix_NN 5_CD -_: 6_CD
        yrs_NNS ,_, mix_NN 10_CD -_: 12_CD yrs_NNS ;_: patient_NN 3_CD a_DT /_NN 3_CD a-d_JJ ;_: patient_NN 3_CD b_SYM /_NN 3_CD b-d_JJ )_) ._. As_IN
        above_IN ,_, this_DT indicates_VBZ that_IN experimental_JJ variability_NN from_IN
        laboratory_NN procedures_NNS or_CC different_JJ arrays_NNS is_VBZ a_DT relatively_RB
        minor_JJ factor_NN in_IN interpretation_NN of_IN results_NNS ._. Mixed_VBN samples_NNS
        from_IN different_JJ regions_NNS of_IN the_DT same_JJ biopsies_NNS showed_VBD the_DT
        same_JJ ,_, or_CC only_RB slightly_RB more_JJR variation_NN (_( mixed_JJ controls_NNS c_SYM 1_CD ,_,
        c_SYM 2_CD ,_, and_CC c_SYM 3_CD ,_, mixed_JJ DMD_NNP 6_CD -_: 9_CD yrs_NNS )_) ._. This_DT showed_VBD that_DT sample_NN
        mixing_VBG does_VBZ indeed_RB average_VB out_IN tissue_NN heterogeneity_NN
        (_( intra-patient_JJ variability_NN )_) ,_, as_RB well_RB as_IN inter-patient_JJ
        variability_NN ._. We_PRP noted_VBD that_IN all_DT of_IN the_DT controls_NNS (_( both_DT male_NN
        and_CC female_JJ )_) clustered_VBN in_IN the_DT same_JJ branch_NN of_IN the_DT dendrogram_NN ,_,
        while_IN the_DT four_CD of_IN the_DT six_CD mixed_JJ DMD_NNP profiles_NNS clustered_VBN just_RB
        one_CD level_NN away_RB from_IN the_DT controls_NNS ,_, separately_RB from_IN the_DT other_JJ
        DMD_NNP profiles_NNS ._. This_DT analysis_NN suggests_VBZ that_IN there_EX is_VBZ
        considerable_JJ variability_NN in_IN the_DT progressive_JJ tissue_NN
        pathology_NN induced_VBN by_IN dystrophin_NN deficiency_NN ,_, both_DT within_IN a_DT
        patient_NN ,_, and_CC between_IN patients_NNS ._.
        To_TO test_VB the_DT sensitivity_NN and_CC specificity_NN of_IN sample_NN mixing_VBG
        versus_CC individual_NN profiling_VBG ,_, we_PRP defined_VBD differentially_RB
        expressed_VBD genes_NNS using_VBG a_DT two_CD group_NN t-test_JJ (_( GeneSpring_NNP [_NN 28_CD
        29_CD ]_NN )_) ,_, comparing_VBG all_DT 6_CD mixed_JJ control_NN profiles_NNS and_CC the_DT 10_CD
        individual_JJ 5_CD -_: 6_CD yr_NN old_JJ DMD_NNP profiles_NNS ._. Genes_NNP were_VBD retained_VBN
        that_WDT met_VBD specific_JJ p_NN value_NN thresholds_NNS between_IN the_DT two_CD sets_NNS
        of_IN profiles_NNS ._. In_IN parallel_JJ ,_, we_PRP compared_VBD the_DT two_CD corresponding_JJ
        mixed_JJ 5_CD -_: 6_CD yr_NN old_JJ DMD_NNP profiles_NNS to_TO the_DT same_JJ 6_CD mixed_JJ control_NN
        profiles_NNS ._.
        Comparison_NNP of_IN 10_CD individual_JJ 5_CD -_: 6_CD yr_NN Duchenne_NNP dystrophy_NN
        profiles_NNS to_TO 6_CD mixed_JJ controls_NNS revealed_VBD 1_CD ,_, 498_CD genes_NNS showing_VBG
        differential_NN expression_NN with_IN p_NN <_NN 0_CD ._. 05_CD (_( Fig_NNP ._. 5_LS )_) ._.
        Comparison_NNP of_IN the_DT two_CD mixed_JJ Duchenne_NNP dystrophy_NN profiles_NNS to_TO
        the_DT 6_CD mixed_JJ controls_NNS showed_VBD 1_CD ,_, 350_CD genes_NNS with_IN p_NN <_NN 0_CD ._. 05_CD
        (_( Fig_NNP ._. 5_LS A_DT )_) ._. Comparison_NNP of_IN the_DT two_CD gene_NN lists_NNS showed_VBD that_IN 61_CD %_NN
        of_IN differentially_RB regulated_VBN genes_NNS detected_VBN by_IN the_DT 10_CD
        individual_JJ profiles_NNS were_VBD also_RB detected_VBN by_IN the_DT two_CD mixed_JJ
        profiles_NNS ._. This_DT suggests_VBZ that_IN the_DT sensitivity_NN and_CC
        specificity_NN of_IN using_VBG mixed_JJ samples_NNS is_VBZ approximately_RB half_NN
        that_IN of_IN individual_JJ profiles_NNS ._. However_RB ,_, there_EX was_VBD a_DT rapid_JJ
        shift_NN in_IN specificity_NN and_CC sensitivity_NN as_IN stringency_NN of_IN the_DT
        analysis_NN was_VBD increased_VBN ._. Raising_VBG the_DT statistical_JJ threshold_NN
        to_TO p_NN <_NN 0_CD ._. 0001_CD for_IN individual_JJ profiles_NNS ,_, while_IN keeping_VBG the_DT
        threshold_NN for_IN mixed_JJ profiles_NNS at_IN p_NN <_NN 0_CD ._. 05_CD as_IN required_VBN by_IN
        the_DT small_JJ number_NN of_IN data_NNS points_NNS (_( Fig_NNP ._. 5_LS B_NNP )_) ,_, resulted_VBD in_IN a_DT
        sensitivity_NN of_IN 86_CD %_NN for_IN mixed_JJ samples_NNS (_( 351_CD of_IN 408_CD genes_NNS p_NN
        <_NN 0_CD ._. 0001_CD detected_VBD )_) ._. In_IN conclusion_NN ,_, mixing_VBG detected_VBN about_IN
        two_CD thirds_NNS of_IN statistically_RB significant_JJ changes_NNS (_( p_NN <_NN
        0_CD ._. 05_CD )_) ._. Mixing_NNP was_VBD a_DT relatively_RB sensitive_JJ method_NN of_IN
        detecting_VBG the_DT most_RBS highly_RB significant_JJ changes_NNS (_( p_NN <_NN
        0_CD ._. 0001_CD )_) (_( 86_CD %_NN of_IN changes_NNS detected_VBD )_) ,_, however_RB it_PRP was_VBD not_RB very_RB
        specific_JJ ;_: as_RB many_JJ as_IN one_CD third_NN of_IN gene_NN expression_NN changes_NNS
        showing_VBG p_NN <_NN 0_CD ._. 05_CD in_IN mixed_JJ samples_NNS were_VBD not_RB confirmed_VBN by_IN
        individual_JJ profiles_NNS ._.
        Use_NN of_IN t-test_JJ measurements_NNS is_VBZ expected_VBN to_TO contain_VB
        significant_JJ amounts_NNS of_IN noise_NN ,_, due_JJ to_TO the_DT very_RB large_JJ number_NN
        of_IN comparisons_NNS involved_VBN in_IN array_NN studies_NNS ;_: a_DT value_NN of_IN p_NN =_SYM
        0_CD ._. 05_CD means_VBZ that_IN as_RB many_JJ as_IN 5_CD %_NN of_IN gene_NN expression_NN changes_NNS
        are_VBP expected_VBN to_TO be_VB identified_VBN by_IN "_'' chance_NN "_'' ,_, and_CC thereby_RB not_RB
        reflect_VB true_JJ differences_NNS between_IN samples_NNS ._. We_PRP have_VBP
        previously_RB reported_VBN a_DT very_RB simple_JJ ,_, yet_RB potentially_RB more_RBR
        stringent_JJ method_NN for_IN data_NNS analysis_NN of_IN small_JJ numbers_NNS of_IN
        expression_NN profiles_NNS ,_, using_VBG duplicate_VB profiles_NNS for_IN control_NN
        and_CC experimental_JJ samples_NNS ,_, and_CC then_RB identifying_VBG those_DT genes_NNS
        that_WDT show_NN consistent_JJ changes_NNS >_NN 2_CD -_: fold_VB in_IN the_DT four_CD
        possible_JJ pair-wise_JJ data_NNS comparisons_NNS (_( four_CD comparison_NN
        survival_NN method_NN )_) [_NN 23_CD ]_NN ._. A_DT similar_JJ pair-wise_JJ comparison_NN
        method_NN ,_, using_VBG a_DT less_RBR stringent_JJ average_JJ fold-change_JJ
        analysis_NN ,_, was_VBD recently_RB reported_VBN for_IN muscle_NN from_IN aging_VBG and_CC
        calorie-restricted_JJ mouse_NN muscle_NN [_NN 13_CD ]_NN ._.
        To_TO investigate_VB the_DT validity_NN of_IN this_DT approach_NN we_PRP compared_VBD
        the_DT sensitivity_NN and_CC specificity_NN of_IN t-test_JJ detection_NN of_IN
        expression_NN changes_NNS versus_CC the_DT four-pairwise_JJ survival_NN
        method_NN ._. Two_CD sample_NN t-test_JJ of_IN the_DT 10_CD individual_JJ Duchenne_NNP
        dystrophy_NN profiles_NNS compared_VBN to_TO the_DT 6_CD mixed_JJ control_NN profiles_NNS
        revealed_VBD 1_CD ,_, 498_CD genes_NNS showing_VBG p_NN <_NN 0_CD ._. 05_CD as_IN above_IN ._. In_IN
        parallel_JJ ,_, the_DT mixed_JJ DMD_NNP duplicate_VB profiles_NNS were_VBD compared_VBN to_TO
        a_DT single_JJ pair_NN of_IN mixed_JJ control_NN sample_NN profiles_NNS (_( c_SYM 1_CD a_DT ,_, c_SYM 1_CD b_SYM )_) ,_,
        using_VBG the_DT pairwise_NN comparison_NN survival_NN method_NN [_NN 23_CD ]_NN ._.
        Briefly_NNP ,_, four_CD comparisons_NNS were_VBD done_VBN (_( DMD_NNP 1_CD a_DT versus_CC control_NN
        1_CD a_SYM ;_: DMD_NNP 1_CD b_SYM versus_CC control_NN 1_CD a_SYM ;_: DMD_NNP 1_CD a_DT versus_CC control_NN 1_CD b_SYM ;_:
        DMD_NNP 1_CD b_SYM versus_CC control_NN 1_CD b_SYM )_) ,_, and_CC only_RB those_DT genes_NNS retained_VBD
        which_WDT showed_VBD >_NN 2_CD -_: fold_VB change_NN in_IN all_DT four_CD comparisons_NNS ._.
        This_DT method_NN was_VBD indeed_RB considerably_RB more_RBR specific_JJ in_IN
        identifying_VBG significant_JJ (_( p_NN <_NN 0_CD ._. 05_CD )_) gene_NN expression_NN
        changes_NNS (_( Fig_NNP ._. 6_CD A_DT )_) with_IN 85_CD %_NN of_IN gene_NN expression_NN changes_NNS in_IN
        the_DT mixed_JJ profiles_NNS verified_VBN by_IN individual_JJ profiles_NNS (_( p_NN <_NN
        0_CD ._. 05_CD )_) ._. The_DT sensitivity_NN of_IN this_DT method_NN depended_VBD on_IN the_DT
        p-value_JJ threshold_NN for_IN the_DT individual_JJ profiles_NNS ,_, but_CC only_RB
        reached_VBD a_DT maximum_NN of_IN 49_CD %_NN sensitivity_NN at_IN p_NN <_NN 0_CD ._. 0001_CD (_( Fig_NNP ._.
        6_CD B_NNP )_) ._.
        The_DT results_NNS above_IN suggested_VBD that_DT analysis_NN of_IN mixed_JJ
        samples_NNS using_VBG t-test_JJ methods_NNS was_VBD relatively_RB sensitive_JJ but_CC
        non-specific_JJ ,_, while_IN analysis_NN of_IN the_DT same_JJ mixed_JJ profiles_NNS by_IN
        2_CD -_: fold_VB survival_NN method_NN was_VBD relatively_RB specific_JJ but_CC
        insensitive_JJ ._. To_TO confirm_VB this_DT conclusion_NN ,_, we_PRP directly_RB
        compared_VBD the_DT sensitivity_NN and_CC specificity_NN of_IN the_DT four_CD
        pairwise_NN comparison_NN method_NN to_TO more_RBR standard_JJ t-test_JJ methods_NNS
        (_( Fig_NNP ._. 7_CD A_DT )_) ._. We_PRP found_VBD that_IN the_DT pairwise_NN survival_NN method_NN was_VBD
        indeed_RB highly_RB specific_JJ ,_, with_IN 97_CD %_NN of_IN changes_NNS identified_VBN by_IN
        this_DT method_NN also_RB detected_VBN by_IN t-test_JJ ._. However_RB ,_, as_IN predicted_VBN ,_,
        it_PRP was_VBD not_RB very_RB sensitive_JJ ,_, with_IN only_RB 30_CD %_NN of_IN the_DT expression_NN
        changes_NNS with_IN p_NN <_NN 0_CD ._. 05_CD identified_VBN by_IN t-test_JJ being_NN
        detected_VBN by_IN the_DT pairwise_NN survival_NN method_NN ._. Comparison_NNP of_IN all_DT
        three_CD analysis_NN methods_NNS showed_VBD that_IN many_JJ (_( 349_CD )_) genes_NNS
        expression_NN changes_NNS were_VBD detected_VBN by_IN all_DT three_CD methods_NNS (_( Fig_NNP ._.
        7_CD B_NNP )_) ._.
      
      
        Conclusions_NNP
        Microarray_NNP data_NNS analyses_NNS have_VBP been_VBN criticized_VBN as_RB being_VBG
        "_'' quite_RB elusive_JJ about_IN measurement_NN reproducibility_NN "_'' [_NN 30_CD ]_NN ._.
        This_DT is_VBZ largely_RB the_DT consequence_NN of_IN the_DT large_JJ number_NN of_IN
        uncontrolled_JJ or_CC unknown_JJ variables_NNS ,_, and_CC the_DT prohibitive_JJ cost_NN
        of_IN isolating_VBG and_CC investigating_VBG each_DT variable_NN ._. Here_RB ,_, we_PRP
        report_VBP the_DT systematic_JJ isolation_NN and_CC study_NN of_IN most_JJS variables_NNS
        in_IN microarray_NN experiments_NNS using_VBG Affymetrix_NNP oligonucleotide_NN
        arrays_NNS and_CC human_JJ tissue_NN biopsies_NNS ._. We_PRP found_VBD that_IN all_DT sources_NNS
        of_IN experimental_JJ variability_NN were_VBD quite_RB minor_JJ (_( microarray_NN R_NN
        2_CD =_SYM 0_CD ._. 98_CD -_: 0_CD ._. 99_CD ;_: probe_NN synthesis_NN +_NN microarray_NN R_NN 2_CD =_SYM 0_CD ._. 98_CD -_: 0_CD ._. 99_CD )_) ._.
        On_IN the_DT other_JJ hand_NN ,_, tissue_NN heterogeneity_NN (_( intra-patient_JJ
        variation_NN ;_: Average_NNP R_NNP 2_CD for_IN 10_CD patients_NNS =_SYM 0_CD ._. 92_CD [_NN 0_CD ._. 85_CD to_TO
        0_CD ._. 98_CD ]_NN )_) ,_, and_CC differences_NNS between_IN individual_JJ patients_NNS (_( SNP_NNP
        noise_NN ;_: Average_NNP R_NNP 2_CD =_SYM 0_CD ._. 76_CD [_NN 0_CD ._. 42_CD to_TO 0_CD ._. 93_CD ]_NN )_) were_VBD major_JJ sources_NNS
        of_IN variability_NN in_IN expression_NN profiling_VBG ._. Thus_RB ,_, tissue_NN
        heterogeneity_NN and_CC SNP_NNP noise_NN have_VBP a_DT high_JJ potential_NN to_TO
        obscure_VB sought_VBN after_IN condition-specific_JJ gene_NN expression_NN
        changes_NNS ,_, particularly_RB in_IN humans_NNS ,_, where_WRB tissue_NN samples_NNS can_MD
        be_VB limiting_VBG (_( sampling_VBG error_NN )_) ,_, and_CC inter-individual_JJ
        variation_NN often_RB is_VBZ very_RB large_JJ ._. We_PRP have_VBP shown_VBN that_IN mixing_VBG of_IN
        patient_NN samples_NNS effectively_RB normalizes_NNS much_JJ of_IN the_DT intra-_NN
        and_CC inter-patient_JJ noise_NN ,_, while_IN still_RB identifying_VBG the_DT
        majority_NN of_IN the_DT most_RBS significant_JJ gene_NN expression_NN changes_NNS
        that_WDT would_MD have_VB been_VBN detected_VBN by_IN larger_JJR numbers_NNS of_IN
        individual_JJ patient_NN profiles_NNS ._. Our_PRP$ results_NNS suggest_VBP that_IN
        stringent_JJ yet_RB robust_JJ data_NNS can_MD be_VB generated_VBN by_IN mixing_VBG a_DT
        small_JJ number_NN of_IN individuals_NNS with_IN a_DT defined_VBN condition_NN (_( n_NN =_SYM
        5_LS )_) ,_, preferably_RB using_VBG different_JJ regions_NNS of_IN tissue_NN for_IN
        duplicate_VB arrays_NNS ._. Controls_NNP should_MD be_VB similarly_RB processed_VBN ._.
        The_DT resulting_VBG four_CD arrays_NNS (_( 2_CD controls_NNS ,_, 2_CD experimental_JJ
        datasets_NNS )_) should_MD then_RB be_VB subjected_VBN to_TO the_DT >_NN 2_CD -_: fold_VB
        survival_NN method_NN ,_, as_RB previously_RB described_VBD [_NN 23_CD ]_NN ._. This_DT will_MD
        yield_VB a_DT stringent_JJ set_NN of_IN expression_NN changes_NNS that_WDT are_VBP likely_JJ
        to_TO be_VB verified_VBN by_IN larger_JJR studies_NNS with_IN individual_JJ arrays_NNS ,_,
        but_CC at_IN low_JJ cost_NN as_RB only_RB four_CD arrays_NNS are_VBP employed_VBN ._. The_DT
        preliminary_JJ data_NN from_IN just_RB four_CD mixed_JJ profiles_NNS (_( two_CD
        experimental_JJ and_CC two_CD control_NN )_) can_MD then_RB be_VB used_VBN to_TO generate_VB
        functional_JJ clusters_NNS and_CC pathophysiological_JJ models_NNS ._. These_DT
        preliminary_JJ models_NNS can_MD then_RB direct_VB more_RBR hypothesis-driven_JJ
        experiments_NNS ,_, or_CC more_RBR extensive_JJ expression_NN profiling_VBG
        studies_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Expression_NNP profiling_VBG
          Human_JJ muscle_NN biopsy_NN samples_NNS were_VBD diagnostic_JJ specimens_NNS
          flash-frozen_JJ immediately_RB after_IN surgery_NN in_IN isopentane_NN
          cooled_VBN in_IN liquid_JJ nitrogen_NN ,_, with_IN storage_NN in_IN small_JJ ,_,
          airtight_NN ,_, humidified_JJ tubes_NNS at_IN -_: 80_CD °_NN C_NNP until_IN RNA_NNP isolation_NN ._.
          Duchenne_NNP muscular_JJ dystrophy_NN patient_NN samples_NNS were_VBD all_DT
          shown_VBN to_TO have_VB complete_JJ lack_NN of_IN dystrophin_NN by_IN
          immunostaining_VBG and_CC /_NN or_CC immunoblot_NN analysis_NN ,_, and_CC were_VBD shown_VBN
          to_TO have_VB excellent_JJ morphology_NN and_CC preservation_NN of_IN tissue_NN ._.
          Controls_NNP included_VBD groups_NNS of_IN males_NNS and_CC female_JJ (_( age_NN
          described_VBD in_IN text_NN )_) that_WDT showed_VBD no_DT histopathological_JJ
          abnormality_NN ,_, normal_JJ dystrophy_NN proteins_NNS ,_, and_CC normal_JJ serum_NN
          creatine_NN kinase_NN levels_NNS ._. Biopsy_NNP sizes_NNS ranged_VBD from_IN 50_CD mg_NN to_TO
          2_CD grams_NNS ,_, with_IN approximately_RB 20_CD -_: 30_CD mg_NN used_VBN for_IN RNA_NNP
          isolation_NN (_( ~_NN 10_CD -_: 15_CD micrograms_NNS of_IN total_JJ RNA_NNP )_) ._. As_IN described_VBD
          in_IN the_DT text_NN ,_, all_DT biopsies_NNS had_VBD two_CD different_JJ regions_NNS of_IN
          the_DT same_JJ biopsy_NN expression_NN profiled_VBN separately_RB ._.
          Details_NNS concerning_VBG the_DT murine_NN profiles_NNS will_MD be_VB
          published_VBN elsewhere_RB ._. In_IN this_DT report_NN ,_, we_PRP used_VBD the_DT murine_NN
          profiles_NNS simply_RB to_TO test_VB the_DT sources_NNS of_IN variation_NN during_IN
          sample_NN preparation_NN prior_RB to_TO hybridization_NN to_TO
          oligonucleotides_NNS ._.
          RNA_NNP isolation_NN (_( Trizol_NNP ,_, Gibco_NNP BRL_NNP )_) ,_, RNA_NNP purification_NN
          (_( RNAeasy_NNP ,_, Qiagen_NNP )_) ,_, cDNA_NN synthesis_NN and_CC biotinylated_JJ cRNA_NN
          were_VBD all_DT done_VBN as_IN per_IN standard_JJ protocols_NNS provided_VBN by_IN
          Affymetrix_NNP Inc_NNP ._. Quality_JJ control_NN methods_NNS are_VBP described_VBN on_IN
          our_PRP$ web_NN site_NN (_(
          http_NN :_: /_NN /_NN microarray_NN ._. cnmcresearch_NN ._. org_NN /_NN pga_NN ._. htm_NN )_) ,_, with_IN cRNA_NN
          amplifications_NNS of_IN between_IN 5_CD -_: and_CC 13_CD -_: fold_VB for_IN each_DT of_IN the_DT
          samples_NNS ._. Ten_CD micrograms_NNS of_IN gel-verified_JJ fragmented_JJ
          biotinylated_JJ cRNA_NN were_VBD hybridized_JJ to_TO each_DT MuscleChip_NNP or_CC
          U_NNP 74_CD A_DT v_NN 2_CD array_NN ,_, and_CC scanning_VBG done_VBN after_IN
          biotin_NN /_NN avidin_NN /_NN phycoerythrin_NN amplification_NN ._. Details_NNS on_IN the_DT
          specific_JJ patients_NNS studied_VBN ,_, and_CC details_NNS for_IN each_DT GeneChip_NNP
          (_( scaling_VBG factors_NNS ,_, number_NN of_IN present_JJ calls_NNS ,_, percentage_NN
          difference_NN calls_VBZ between_IN each_DT duplicate_JJ sample_NN ,_, number_NN of_IN
          difference_NN calls_VBZ surviving_VBG four_CD pair-wise_JJ comparisons_NNS of_IN
          duplicate_VB chips_NNS )_) is_VBZ provided_VBN (_( Table_NNP 1_LS )_) ._. All_DT profiling_VBG
          data_NN presented_VBN here_RB is_VBZ available_JJ on_IN our_PRP$ web_NN site_NN (_(
          http_NN :_: /_NN /_NN microarray_NN ._. CNMCResearch_NNP ._. org_NN ;_: data_NNS link_VBP )_) ,_, as_IN image_NN
          (_( ._. dat_NN )_) ,_, absolute_JJ analysis_NN (_( ._. chp_NN )_) ,_, and_CC ASCII_NNP text_NN
          conversions_NNS of_IN ._. chp_NN (_( ._. txt_NN )_) for_IN each_DT individual_JJ profile_NN
          (_( see_VB http_NN :_: /_NN /_NN microarray_NN ._. cnmcresearch_NN ._. org_NN /_NN pga_NN ._. htmfor_NN file_NN
          descriptions_NNS and_CC use_NN )_) ._.
        
        
          Bio-informatic_NNP methods_NNS
          Absolute_JJ analysis_NN (_( average_JJ difference_NN determinations_NNS
          for_IN each_DT probe_NN set_VBN )_) was_VBD done_VBN using_VBG Affymetrix_NNP default_NN
          parameters_NNS ._. As_IN described_VBD in_IN the_DT text_NN ,_, data_NNS was_VBD analyzed_VBN
          using_VBG a_DT variety_NN of_IN methods_NNS ,_, including_VBG unsupervised_JJ
          nearest-neighbor_JJ hierarchical_JJ clustering_VBG analyses_NNS
          (_( GeneSpring_NNP [_NN 28_CD 29_CD ]_NN [_NN Silicon_NNP Genetics_NNP ]_NN ,_, and_CC Cluster_NNP [_NN
          25_CD ]_NN [_NN Stanford_NNP University_NNP ]_NN )_) ,_, t-test_JJ (_( GeneSpring_NNP )_) and_CC
          four-comparison_JJ survival_NN method_NN [_NN 23_CD ]_NN ._. The_DT Cluster_NNP and_CC
          Tree_NN View_NNP software_NN were_VBD download_NN from_IN
          http_NN :_: /_NN /_NN rana_NN ._. lbl_NN ._. govand_NN installed_VBN on_IN an_DT NT_NNP
          workstation_NN ._.
        
      
    
  
